Comparison · NCT01014013-sae
MK0826 vs Ceftriaxone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MK0826 vs Ceftriaxone: serious adverse events. Trial comparisons, record NCT01014013-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01014013-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0528 | 0.152 | wilson | |
| Risk in group 2 | 0.0593 | 0.0303 | 0.113 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0316 | -0.0339 | 0.0994 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.648 | 3.63 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 0.627 | 4.02 | log | |
| Number needed to harm, for one more participant with a serious adverse event on MK0826 than on Ceftriaxone | 31.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MK0826 | MK0826 as a single daily dose of 1.0 g intravenous infusion and be switched to oral ciprofloxacin at a dose of 500 mg twice daily and patients who received at least 1 dose of parentheral therapy | 12 | 132 | EG000 |
| Group 2 | Ceftriaxone | Ceftriaxone sodium as a single daily dose of 2.0 g intravenous infusion and be switched to oral ciprofloxacin at a dose of 500 mg twice daily and patients who received at least 1 dose of parentheral therapy | 8 | 135 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse experiences were recorded during parenteral therapy and for 14 days after the end of study therapy including oral study therapy (safety follow-up period)
Source ClinicalTrials.gov
Trial
- Title
- Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
- NCT number
- NCT01014013
- Phases
- PHASE3
- Conditions
- Urinary Tract Infection
- Interventions
- ertapenem sodium (MK0826), Comparator: ceftriaxone sodium
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2010-03-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01014013?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01014013-sae